論文・技術情報追加のお知らせ

1. Immune checkpoint Inhibitor related myocarditis reported through the FDA adverse event reporting system: pharmacovigilance trends in reporting and outcomes.

免疫チェックポイント阻害薬による心筋炎の報告増加、致死率低下

対象DB：FAERS

2. Herpes Zoster Infections With Multiple Sclerosis Disease-Modifying Therapies: A Real-World Pharmacovigilance Study.

免疫抑制型MS治療薬は帯状疱疹のリスク増加と関連

対象DB：FAERS,VAERS

3. Finasteride Use: Evaluation of Depression and Suicide Risk.

フィナステリドと抑うつ・自殺リスクの関連が示唆

対象DB：FAERS

4. Antiepileptic drugs and foetal disorders: analysis of 20-year data from the pharmacovigilance center.

AEDの併用が胎児障害に与える影響を明確化

対象DB：FAERS

5. Signal mining and analysis of ripretinib adverse events: a real-world pharmacovigilance analysis based on the FAERS database.

リプレチニブ関連の予期せぬ副作用が発見

対象DB：FAERS

6. Characterizing Cardiotoxicity of FDA-Approved Soft Tissue Sarcoma Targeted Therapies and Immune Checkpoint Inhibitors: A Systematic Review.

STS治療薬は心血管のリスク増加と関連

対象DB：FAERS

7. Off-the-Shelf Large Language Models for Causality Assessment of Individual Case Safety Reports: A Proof-of-Concept with COVID-19 Vaccines.

ChatGPTはワクチン因果評価で優れた結果を示した

対象DB：FAERS,VAERS

8. Analysis and mining of Dupilumab adverse events based on FAERS database.

デュピルマブに関する副作用シグナルを検出

対象DB：FAERS

9. Mining and analysis of amphotericin B adverse reaction signals: a real-world study based on the FAERS database.

アンフォテリシンBの副作用シグナルを分析

対象DB：FAERS

10. Post-marketing safety of elacestrant in breast cancer: a pharmacovigilance investigation using the FDA adverse event reporting system.

エラスエストラントのAE解析。新たなリスク因子が確認

対象DB：FAERS

11. Post-market safety profile of cefiderocol: a real-world pharmacovigilance exploratory analysis based on U.S. FDA adverse event reporting system (FAERS).

セフィデロコルの副作用シグナルを分析

対象DB：FAERS

12. Drug-associated gingival disorders: a retrospective pharmacovigilance assessment using disproportionality analysis.

薬剤による歯茎障害の関連を評価

対象DB：FAERS,VAERS

13. The real-world safety profile of sertraline: Pharmacovigilance analysis of the FAERS database.

セルトラリンの副作用に関する新たなシグナルを特定

対象DB：FAERS

14. Comprehensive evaluation of flumazenil adverse reactions: Insights from FAERS data and signal detection algorithms.

フルマゼニルの副作用に関する解析を実施

対象DB：FAERS

15. Changes in the blood cyclosporine level after switching from voriconazole to isavuconazole in a patient with aplastic anemia: insights from physiologically based pharmacokinetic model simulation and the Adverse Event Reporting System database study.

イサブコナゾールがシクロスポリンに与える影響を検討

対象DB：FAERS

16. Post-marketing safety surveillance of vortioxetine hydrobromide: a pharmacovigilance study leveraging FAERS database.

ボルチオキセチンの副作用をFAERSで分析

対象DB：FAERS

17. Drug-Related Hypertension: A Disproportionality Analysis Leveraging the FDA Adverse Event Reporting System.

薬剤による高血圧リスクをFAERSで調査

対象DB：FAERS

18. Eosinophil-induced adverse events induced by treatment with programmed cell death 1/ligand 1 inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system.

PD-1/PD-L1阻害薬で好酸球誘発の有害事象が発生

対象DB：FAERS

19. Comparative safety signals of dopamine agonists: psychiatric and cardiovascular risks derived from FDA adverse event reporting system (FAERS) data.

ドパミン作動薬の副作用を比較。精神障害が非エルゴ型に多く、治療法選択に影響

対象DB：FAERS

20. Alopecia Associated With the Use of Immune Checkpoint Inhibitors: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System.

免疫チェックポイント阻害薬による脱毛の関連をFAERSで解析

対象DB：FAERS

21. Opposite causal effects of type 2 diabetes and metformin on Alzheimer's disease.

T2Dとメトホルミンがアルツハイマー病に与える影響を解析

対象DB：FAERS

22. Adverse drug reactions to atezolizumab in combination with bevacizumab in hepatocellular carcinoma patients: an analysis of the food and drug administration adverse event reporting system database.

アテゾリズマブとベバシズマブの併用による有害事象をFAERSで分析

対象DB：FAERS

23. Adverse events reporting of edaravone: a real-world analysis from FAERS database.

エダラボンに関連する有害事象をFAERSで分析

対象DB：FAERS

24. A Disproportionality Analysis on Benzoyl Peroxide and Its Risk of Malignancy Using the FDA Adverse Event Reporting System.

ベンゾイル過酸化物と悪性腫瘍の関連性分析

対象DB：FAERS

25. Exploring Connections Between Weight-Loss Medications and Thyroid Cancer: A Look at the FDA Adverse Event Reporting System Database.

GLP-1受容体作動薬と甲状腺癌の関連

対象DB：FAERS

26. A real-world pharmacovigilance study of omalizumab using disproportionality analysis in the FDA adverse drug events reporting system database.

オマリズマブの安全性に関する実データ分析

対象DB：FAERS

27. Lipid-lowering and antihypertensive drugs on aortic disease risk: insights from Mendelian randomization analysis and real-world pharmacovigilance data.

スタチンとPCSK9iは大動脈疾患に有効

対象DB：FAERS

28. Unravelling Cocoa Drying Technology: A Comprehensive Review of the Influence on Flavor Formation and Quality.

ココアの乾燥法が風味成分に与える影響

対象DB：JADER

29. Analysis of Bevacizumab-Induced Gastrointestinal Perforation Using the Japanese Adverse Drug Event Report Database.

非小細胞肺癌患者では、ビバスチンによる消化管穿孔の発症が早期に起こる

対象DB：JADER

30. Hospitalization of patients with Down syndrome in acute care hospitals in Japan.

ダウン症患者は40歳以降、誤嚥性肺炎や認知症、骨折の発症が増加

対象DB：DPC

31. Association of impaired levels with outcomes for cervical fracture dislocation using the Japanese diagnosis procedure combination database.

高位CFDは呼吸器合併症の発生率が高い

対象DB：DPC

32. Association of once-daily single-device dual bronchodilators with prevention of rehospitalization for chronic obstructive pulmonary disease: a retrospective national inpatient database study.

DPI使用はSMIより心血管疾患再入院減少

対象DB：DPC

33. Association Between the Intensity and Frequency of Swallowing Rehabilitation and Oral Intake at Discharge in Older Patients with Acute Post-stroke Dysphagia.

早期嚥下リハの頻度と強度で経口摂取改善

対象DB：DPC

34. Effectiveness of Switching from Multiple-Inhaler to Once-Daily Single-Inhaler Triple Therapy in Patients with COPD in a Real-World Setting in Japan.

単一吸入器FF/UMEC/VIへの変更で増悪減少

対象DB：MDV

35. Secukinumab Persistence in Patients with Psoriatic Arthritis: An Adalimumab-Matched Retrospective Cohort Database Study (FLYWAY).

セクキヌマブはアダリムマブより継続率が高い

対象DB：MDV

36. Safety of iGlarLixi in Japanese People with Type 2 Diabetes: A Post-marketing Database Study.

iGlarLixiは重篤な血糖異常のリスクが低い

対象DB：MDV

37. Exogenous sex steroid hormones and asthma phenotypes: a study protocol for a prospective cohort analysis with UK-wide primary care data.

女性ホルモンと喘息の関係をCPRDで解析

対象DB：CPRD

38. Atrial fibrillation development in the heart failure population from nationwide British linked electronic health records.

心不全患者の新規心房細動発症リスク因子を解析

対象DB：CPRD

39. Caution in Handling Switchers in Pharmacoepidemiologic Studies Estimating Treatment Effects: The Example of Dipeptidyl Peptidase-4 Inhibitors and Inflammatory Bowel Disease.

DPP4阻害薬のIBDリスクは研究デザイン依存

対象DB：CPRD

40. Prescription Refill Adherence Before and After Patient Portal Registration in Among General Practice Patients in England Using the Clinical Practice Research Datalink: Longitudinal Observational Study.

患者ポータル登録後、スタチン服薬遵守率が低下

対象DB：CPRD